



HAL
open science

Some DNM2 mutations cause extremely severe congenital myopathy and phenocopy myotubular myopathy

Valérie Biancalana, Norma Romero, Inger Johanne Thuestad, Jaakko Ignatius, Janne Kataja, Maria Gardberg, Dephine Héron, Edoardo Malfatti, Anders Oldfors, Jocelyn Laporte

► To cite this version:

Valérie Biancalana, Norma Romero, Inger Johanne Thuestad, Jaakko Ignatius, Janne Kataja, et al.. Some DNM2 mutations cause extremely severe congenital myopathy and phenocopy myotubular myopathy. *Acta Neuropathologica Communications*, 2018, 6 (1), 10.1186/s40478-018-0593-2 . hal-03671916

HAL Id: hal-03671916

<https://hal.science/hal-03671916v1>

Submitted on 18 May 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

LETTER TO THE EDITOR

Open Access



Some DNM2 mutations cause extremely severe congenital myopathy and phenocopy myotubular myopathy

Valérie Biancalana^{1,2,3,4,5*} , Norma B. Romero^{6,7,8}, Inger Johanne Thuestad⁹, Jaakko Ignatius¹⁰, Janne Kataja¹¹, Maria Gardberg¹², Delphine Héron¹³, Edoardo Malfatti^{7,8}, Anders Oldfors¹⁴ and Jocelyn Laporte^{2,3,4,5}

Keywords: *DNM2*, *MTM1*, Congenital myopathy, Centronuclear myopathy, Hypotonia

Centronuclear myopathies (CNM) are rare congenital myopathies characterized by muscle weakness with facial and eye involvement and intracellular disorganisation of myofibers with centralized nuclei [5, 8]. Several forms and mode of inheritance have been described. The most severe form, also called X-linked myotubular myopathy, is due to *MTM1* mutations and is associated with perinatal severe hypotonia and respiratory distress leading to death of most affected boys in infancy (MIM#310400) [7]. Dominant *DNM2* mutations are linked to milder cases with either neonatal, childhood or adult onset and proximal or diffuse muscle weakness (MIM#160150) [2, 3]. Previously described neonatal *DNM2* cases showed gradual improvement in motor function and survival into adulthood [1]. Unlike *MTM1*-CNM, reported cases of *DNM2*-CNM biopsies often show a radial distribution of sarcoplasmic strands on cross sections. Here we present three unrelated *DNM2*-CNM cases resembling myotubular myopathy at the clinical and histopathological levels.

Two girls and one boy from unrelated families presented at birth with global and severe hypotonia with respiratory distress requiring invasive and permanent respiratory support (Additional file 1: Table S1). Patients 1 and 2 had multiple contractures. Patient 1 is a male born at 29 weeks of estimated gestational age (EGA), presenting with foetal akinesia and disturbance of cardiac rhythm. Hydramnios was detected. He had a

congenital and bilateral chylothorax and died at 5 weeks from a bronchopulmonary dysplasia. Patient 2 is a girl delivered at term by cesarean section due to monotonic heart rate. No amniotic fluid was present. She presented with small intracerebral hemorrhages but no major brain malformations at 1.5 months, and developed 40 degrees convex scoliosis by 4 months. Extubation attempt at 5 months failed and she died at 8 months of age from pneumonia. Patient 3 is a girl born at 34 weeks of EGA. She had a bilateral ptosis and high-arched palate. Brain MRI uncovered a leukoencephalopathy with enlarged ventricles and reduced white matter. She died at 4 months from respiratory failure.

Muscle biopsies were performed at 1 month from quadriceps for patients 1 and 3 and at autopsy at 8 months for patient 2. They showed fiber size variability and hypotrophic muscle fibers with prominent nuclear centralizations (Fig. 1a). No clusters of nuclei were observed (Additional file 1: Figure S1). NADH-TR staining revealed centrally located hyperintense reaction in the majority of fibers, without radial distribution of sarcoplasmic strands as the spokes of a wheel. Predominance of type 1 fiber was observed for patient 2 with more variability in fiber size and some increase in connective tissue. Electron microscopy ultrastructural analysis in patient 1 confirmed the presence of prominent nuclear centralizations. Of note centralized nuclei were surrounded by amorphous material and partially disorganized and misaligned sarcomeres. Satellite cells count appeared normal unlike neonates with myotubular myopathy in whom a decrease was noted [9] (Fig. 1b).

MTM1 mutations were excluded in patients 1 and 3. All the patients were found with heterozygous de novo *DNM2* mutations, NM_001005360.2: c.1831G > A -

* Correspondence: valerie.biancalana@chru-strasbourg.fr

¹Laboratoire Diagnostic Génétique, Faculté de Médecine, CHRU, Nouvel Hôpital Civil, 1 place de l'Hôpital, 67091 Strasbourg, France

²Institut de Génétique et de Biologie Moléculaire et Cellulaire, IGBMC, Illkirch, France

Full list of author information is available at the end of the article






Fig. 1 a. Hematoxylin-eosin (HE) and nicotinamide adenosine dinucleotide-tetrazolium reductase (NADH-TR) staining of muscles from the patients, showing fibers with centralized nuclei (HE) and abnormal central accumulation oxidative staining and a paler peripheral halo. Scale bars 20 μ m. **b.** Electron microscopy of patient 1 muscle showing partial sarcomeres disorganisation and central nuclei. Scale bar 10 μ m. **c.** Localization of presently reported mutations (dark blue) compared to known *DNM2*-CNM mutations (red) on the 3D model of nucleotide-free human *DNM1* (PDB 3SNH). They all clusterize at the PH (yellow) – Middle/stalk (light blue) interface (green line)

p.Glu611Lys, c.1090C > T - p.Arg364Cys, and c.1856C > T - p.Ser619Leu for patient 1, 2 and 3 respectively, through direct Sanger sequencing or an arthrogyposis gene panel (CeGaT, Tübingen, Germany). The p.Ser619Leu mutation was reported in at least 11 CNM cases with neonatal onset and a milder course compared to the present cohort. Mutations p.Glu611Lys and p.Arg364Cys are novel and are not found in gnomAD (<http://gnomad.broadinstitute.org/>). They affect aminoacids conserved down to drosophila and are predicted pathogenic by SIFT and Polyphen-2. Furthermore, they cluster with most known mutations on the 3D structure (Fig. 1c).

Here we report the most severe CNM patients with heterozygous *DNM2* mutations. Compared to previously reported *DNM2*-CNM cases [3], they were fully dependent on invasive ventilation and all died within the first months of life. The very early lethal outcome in patient 1 may have been influenced by concomitant prematurity. Nevertheless, the three patients did not improve except for a slight muscle strength enhancement appearing after 6 months of age in patient 2. Furthermore, early developmental milestones were delayed

(Additional file 1: Table S1), in contrast with some previously described neonatal onset *DNM2* patients [4]. This study enlarges the clinical and genetic spectrum of *DNM2*-CNM. Moreover, it underlines that *DNM2* mutations can be associated with decreased survival.

In addition to a CNM phenotype, the 3 patients display similar features with the lethal congenital contracture syndrome (MIM#615368) due to a *DNM2* homozygous mutation [6], especially multiple contractures, fetal hypokinesia, pulmonary hypertension, brain hemorrhages, and abnormal fetal heart rhythm.

The present *DNM2*-CNM cases were highly similar to myotubular myopathy due to *MTM1* mutations, although none of them presented with the association of facial hypotonia, ptosis, ophthalmoplegia and elongated face that is typical in *MTM1*-CNM cases. In addition to the perinatal severity, they had very severe hypotonia, respiratory distress and the same histopathological findings, lacking the radial strands hallmark of most other *DNM2* cases.

In conclusion, *DNM2* should be investigated in congenital myopathies presenting as myotubular myopathy.

Additional file

Additional file 1: Clinical, molecular, histopathological and ultrastructural findings for the patients. **Table S1** Clinical and molecular findings in the *DNM2* severe cases. **Figure S1** Histopathological and ultrastructural findings for the patients. Patients 1, 2 and 3: Hematoxylin-eosin (HE) staining of muscles showing fibers with centralized nuclei. Patient 1: ATPase at pH 9.4 showing type I (pale) and type II (dark) fibers. Patient 3: ATPase at pH 4.6 showing type 1 fibers dark and type 2 fibers less stained. Scale bars 20 μ m. (ZIP 46909 kb)

Abbreviations

CNM: Centronuclear myopathies; DNM2: Dynamin 2; EGA: Estimated gestational age; HE: Hematoxylin-eosin; MRI: Magnetic resonance imaging; MTM1: Myotubularin 1; NADH-TR: Nicotinamide adenine dinucleotide tetrazolium reductase

Acknowledgements

We thank Carina Wallgren-Pettersson for suggestions and Nicolas Dondaine and Mai Thao Bui for technical assistance.

Funding

Supported by Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université de Strasbourg, Association Française contre les Myopathies (AFM).

Availability of data and materials

All data generated or analysed during this study are included in this published article [and its Additional files].

Authors' contributions

VB, NBR, AO and JL directed the study; IJT, JK and DH performed clinical examination; NBR, EM, MG and AO performed histological examinations; VB and JL analyzed the data and wrote the manuscript with input from other authors. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All procedures involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Consent for publication

Informed consent was obtained from all individual participants included in the study.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Laboratoire Diagnostic Génétique, Faculté de Médecine, CHRU, Nouvel Hôpital Civil, 1 place de l'Hôpital, 67091 Strasbourg, France. ²Institut de Génétique et de Biologie Moléculaire et Cellulaire, IGBMC, Illkirch, France. ³Centre National de la Recherche Scientifique, CNRS UMR7104, Illkirch, France. ⁴Institut National de la Santé et de la Recherche Médicale, INSERM, U964, Illkirch, France. ⁵Université de Strasbourg, Illkirch, France. ⁶Center for Research in Myology, GH Pitié-Salpêtrière, Sorbonne Universités, UPMC Univ Paris 06, INSERM UMRS974, CNRS FRE3617, Paris, France. ⁷Neuromuscular Morphology Unit, Myology Institut, GH La Pitié-Salpêtrière, Paris, France. ⁸Centre de référence de Pathologie Neuromusculaire Paris-Est, Institut de Myologie, CHU Paris-GH La Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France. ⁹Department of Pediatrics, Skane University Hospital, Malmo, Sweden. ¹⁰Department of Clinical Genetics, Turku University Hospital, Turku, Finland. ¹¹Department of Paediatrics and Adolescent Medicine, Turku University Hospital, Turku, Finland. ¹²Department of Pathology, Turku

University Hospital and Institute of Biomedicine, Turku University, Turku, Finland. ¹³Service de Génétique clinique et Médicale, CHU Paris-GH La Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France. ¹⁴Department of Pathology, and Genetics, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.

Received: 14 August 2018 Accepted: 31 August 2018

Published online: 12 September 2018

References

1. Bitoun M, Bevilacqua JA, Prudhon B et al (2007) Dynamin 2 mutations cause sporadic . Centronuclear myopathy with neonatal onset. *Ann Neurol* 62:666–670
2. Bitoun M, Maugendre S, Jeannot PY et al (2005) Mutations in dynamin 2 cause dominant centronuclear myopathy. *Nat Genet* 37:1207–1209
3. Bohm J, Biancalana V, Dechene ET et al (2012) Mutation spectrum in the large GTPase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy. *Hum Mutat* 33:949–959
4. Catteruccia M, Fattori F, Codemo V, Ruggiero L, Maggi L, Tasca G, Fiorillo C, Pane M, Berardinelli A, Verardo M et al (2013) Centronuclear myopathy related to dynamin 2 mutations: clinical, morphological, muscle imaging and genetic features of an Italian cohort. *Neuromuscul Disord* 23:229–238
5. Jungbluth H, Wallgren-Pettersson C, Laporte J (2008) Centronuclear (myotubular) myopathy. *Orphanet J Rare Dis* 3:26
6. Koutsopoulos OS, Kretz C, Weller CM et al (2013) Dynamin 2 homozygous mutation in humans with a lethal congenital syndrome. *Eur J Hum Genet* 21:637–642
7. Laporte J, Hu LJ, Kretz C, Mandel JL, Kioschis P, Coy JF, Klauck SM, Poustka A, Dahl N (1996) A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast. *Nat Genet* 13:175–182
8. Romero NB (2010) Centronuclear myopathies: a widening concept. *Neuromuscul* 20:223–228
9. Shichiji M, Biancalana V, Fardeau M et al (2013) Extensive morphological and immunohistochemical characterization in myotubular myopathy. *Brain Behav* 3:476–486

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

